McKesson (MCK) Price & Analysis

5 Followers

MCK Stock Chart & Stats

€739.20

€17.40(2.41%)

At close: Jul 24 4:00 PM EDT

€739.20

€17.40(2.41%)

Day’s Range― - ―

52-Week Range€562.00 - €865.80

Previous CloseN/A

Volume8.00

Average Volume (3M)8.00

Market Cap

€86.89B

Enterprise Value€112.06K

Total Cash (Recent Filing)€3.98B

Total Debt (Recent Filing)€8.61B

Price to Earnings (P/E)22.2

Beta-0.04

Next Earnings

Aug 05, 2026

EPS Estimate

8.29

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)38.64

Shares Outstanding117,077,740

10 Day Avg. Volume15

30 Day Avg. Volume8

Financial Highlights & Ratios

PEG Ratio0.46

Price to Book (P/B)-49.24

Price to Sales (P/S)0.27

P/FCF Ratio18.70

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€814.09

Price Target Upside10.13% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

EPS Forecast (FY)38.82

Revenue Forecast (FY)€378.19B

Bulls Say, Bears Say

Bulls Say

Scale & Revenue GrowthSustained, large-scale revenue growth underscores McKesson’s dominant distribution scale and broad customer relationships. That scale supports durable purchasing leverage with manufacturers, high fixed-cost absorption across logistics, and resilience to demand shifts — advantages that persist over multiple quarters.

Strong Cash Generation & Capital AllocationConsistent operating and free cash flow provide structural capacity to fund share repurchases, dividends, and strategic investments. Strong cash conversion lets management prioritize balance-sheet repairs and separation financing while preserving the ability to invest in automation and specialty services over the medium term.

Oncology & Specialty MomentumRapid, scalable growth in oncology and multispecialty services diversifies McKesson away from low‑margin commoditized distribution. Provider additions, targeted acquisitions and higher-value service lines can sustainably lift segment operating profit and reduce exposure to branded/generic pricing cycles over the coming quarters.

Bears Say

Structurally Thin MarginsVery low gross and net margins mean limited slack for cost inflation, pricing pressure, or mix shifts. Even modest declines in purchasing spreads or increased operating costs can disproportionately erode earnings, making profitability sensitive despite high revenue scale and increasing the importance of higher‑margin specialty growth.

Legacy Balance Sheet Weakness & LeverageAlthough equity has turned positive, the prior negative-equity history and meaningful leverage constrain financial flexibility. Dependence on external financing and a meaningful debt load raise refinancing and covenant risk, complicating large corporate actions like the Medical‑Surgical separation and limiting downside protection.

Free Cash Flow Volatility & Separation-Related CostsMaterial FCF volatility reduces predictability for buybacks, dividends and separation funding. Planned separation financing and higher interest expense compress near‑term cash available for operations and investments, increasing execution risk and elevating sensitivity to working‑capital swings in distribution.

McKesson News

McKesson price target raised to $1,000 from $945 at Citi

Citi raised the firm’s price target on McKesson (MCK) to $1,000 from $945 and keeps a Buy rating...

10d ago

MCK

This Healthcare Giant Just Raised Its Dividend 15%

This is the 10th consecutive dividend increase. ...

11d ago

MCK

McKesson board increases quarterly dividend 15% to 94c per share

The Board of Directors of McKesson (MCK) Corporation declared a regular dividend of $0.94 per share of common...

11d ago

MCK

McKesson price target raised to $925 from $900 at BofA

BofA raised the firm’s price target on McKesson (MCK) to $925 from $900 and keeps a Buy rating...

12d ago

MCK

McKesson price target lowered to $989 from $1,012 at TD Cowen

TD Cowen lowered the firm’s price target on McKesson (MCK) to $989 from $1,012 and keeps a Buy...

12d ago

MCK

McKesson Shareholders Back Board, Auditors, and Executive Pay

McKesson ( ($MCK) ) has provided an announcement. On July 22, 2026, McKesson Corporation held its Annual Meeting...

9d ago

MCK

McKesson Appoints New Executive Vice President, Strategy Chief

McKesson ( ($MCK) ) has shared an announcement. McKesson announced a leadership change to support an orderly transition...

1M ago

MCK

How High Can the Price of McKesson Stock (MCK) Rise? One Top Analyst Says a 35% Upside Is Possible

McKesson stock gained on Wednesday and one Wall Street analysts expects the shares to continue to rally. ...

1M ago

MCK

Cencora price target raised to $285 from $280 at BofA

BofA analyst Allen Lutz raised the firm’s price target on Cencora (COR) to $285 from $280 and keeps...

1M ago

COR

Charles Rhyee Reiterates Buy on McKesson, Keeps $1,012 Price Target on Steady Long-Term Earnings Outlook

TD Cowen analyst Charles Rhyee has maintained their bullish stance on MCK stock, giving a Buy rating on...

2M ago

MCK

McKesson Expands Capital Structure with New Term Loan

An update from McKesson ( ($MCK) ) is now available. On June 9, 2026, McKesson subsidiaries including McKesson...

2M ago

MCK

McKesson price target lowered to $925 from $1,050 at Barclays

Barclays lowered the firm’s price target on McKesson (MCK) to $925 from $1,050 and keeps an Overweight rating...

2M ago

MCK

McKesson Buy Rating Reaffirmed as GLP-1 Positioning Supports Outlook; $900 Price Target Maintained

In a report released yesterday, Allen Lutz from Bank of America Securities maintained a Buy rating on McKesson,...

2M ago

MCK

McKesson closes investment with Apollo Funds for minority interest in MMS

McKesson (MCK) announced the successful completion of the previously announced minority ownership interest investment from funds managed by...

2M ago

APO

MCK

MCK FAQ

What was Mckesson Corp.’s price range in the past 12 months?

Mckesson Corp. lowest stock price was €562.00 and its highest was €865.80 in the past 12 months.

What is Mckesson Corp.’s market cap?

Mckesson Corp.’s market cap is €86.89B.

When is Mckesson Corp.’s upcoming earnings report date?

Mckesson Corp.’s upcoming earnings report date is Aug 05, 2026 which is in 3 days.

How were Mckesson Corp.’s earnings last quarter?

Mckesson Corp. released its earnings results on May 07, 2026. The company reported €10.133 earnings per share for the quarter, beating the consensus estimate of €10.025 by €0.108.

Is Mckesson Corp. overvalued?

According to Wall Street analysts Mckesson Corp.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Mckesson Corp. pay dividends?

Mckesson Corp. does not currently pay dividends.

What is Mckesson Corp.’s EPS estimate?

Mckesson Corp.’s EPS estimate is 8.29.

How many shares outstanding does Mckesson Corp. have?

Mckesson Corp. has 117,077,740 shares outstanding.

What happened to Mckesson Corp.’s price movement after its last earnings report?

Mckesson Corp. reported an EPS of €10.133 in its last earnings report, beating expectations of €10.025. Following the earnings report the stock price went up 1.624%.

Which hedge fund is a major shareholder of Mckesson Corp.?

Currently, no hedge funds are holding shares in DE:MCK

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

McKesson Stock Smart Score

Outperform

Fundamentals

Return on Equity

0.39%

Trailing 12-Months

Asset Growth

9.56%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Mckesson Corp.

McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.

McKesson (MCK) Earnings & Revenues

Historic Earnings Reports

MCK Company Deck

MCK Earnings Call

Q4 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

McKesson reported a strong fiscal 2026 with double-digit revenue, operating profit and EPS growth, robust cash generation and material progress on strategic initiatives (oncology expansion, biopharma scale, supply chain modernization, and Medical‑Surgical separation). The company is returning significant capital to shareholders and reaffirmed long‑term targets. Offsetting risks include branded pricing pressure (IRA effects), sequential GLP‑1 volatility, ongoing integration and corporate expense investments, and near‑term cash flow/interest impacts related to separation financing. On balance the positives (broad-based growth, margin expansion, cash returns, strategic progress) outweigh the negatives, though the business faces near-term variability and execution/approval risks tied to the Medical‑Surgical separation.View all DE:MCK earnings summaries

MCK Revenue Breakdown

83.45% North American Pharmaceutical

12.00% Oncology & Multispecialty

1.44% Prescription Technology Solutions

2.85% Medical-Surgical Solutions

0.26% Other

MCK Stock 12 Month Forecast

Average Price Target

€814.09

▲(10.13% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"580":"€580","913":"€913","663.25":"€663.3","746.5":"€746.5","829.75":"€829.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":912.1773045,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€912.18</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":814.0886281200001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€814.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":705.41711548,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€705.42</span>\n  </div></div>","useHTML":true}}],"tickPositions":[580,663.25,746.5,829.75,913],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,670.8,689.3674849615384,707.9349699230769,726.5024548846153,745.0699398461538,763.6374248076922,782.2049097692308,800.7723947307692,819.3398796923077,837.9073646538461,856.4748496153846,875.042334576923,893.6098195384616,{"y":912.1773045,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,670.8,681.8222021630769,692.8444043261538,703.8666064892308,714.8888086523077,725.9110108153847,736.9332129784616,747.9554151415384,758.9776173046154,769.9998194676923,781.0220216307692,792.0442237938462,803.0664259569231,{"y":814.0886281200001,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,670.8,673.4628550369231,676.1257100738461,678.7885651107692,681.4514201476923,684.1142751846154,686.7771302215384,689.4399852584615,692.1028402953846,694.7656953323077,697.4285503692307,700.0914054061539,702.7542604430769,{"y":705.41711548,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":609.902,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":601.735,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":581.419,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":653.514,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":697.985,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":749.933,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":709.413,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":692.646,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":840.678,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":742.186,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":698.434,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":632.8,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":670.8,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >